Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Part of paid clinical trials in Salt Lake City, Utah.

Sponsor
University of Utah
Study ID
NCT06824701
Phase
PHASE1
Status
Suspended

Conditions

  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tazemetostat — DRUG
    Tazemetostat will be self-administered BID as an oral treatment on a 28-day cycle.
  • Zanubrutinib — DRUG
    Zanubrutinib will be self-administered BID as an oral treatment on a 28-day cycle.
  • Rituximab — DRUG
    Rituximab or a biosimilar will be administered intravenously per standard of care.
  • Obinutuzumab — DRUG
    Obinutuzumab will be administered intravenously on days 1, 8, 15 of cycle 1 and then day 1 of cycles 2 to 12.

Study Details

The purpose of this clinical trial is to learn if the study drug Tazemetostat combined with Zanubrutinib and anti-CD20 monoclonal antibody is safe and effective in treating patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma.

Key Dates

Start date
Sep 12, 2025
Status verified
Apr 2026
Primary completion
Jan 31, 2032
Completion
Jan 31, 2033

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment: All Patients
    The study will investigate the effectiveness of Tazemetostat in combination with Zanubrutinib and anti-CD20 monoclonal antibody

Primary Outcome Measure

Maximum Tolerated Dose (MTD) of tazemetostat in combination with zanubrutinib and anti-CD20 mAb [ Time Frame: 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Huntsman Cancer Institute at University of UtaSalt Lake CityUtah84112-

Find similar trials in Salt Lake City, UT

By research site
Huntsman Cancer Institute at University of Uta· Salt Lake City, UT

Related Studies